Alex Kolevzon, MD
Associate Professor of Psychiatry and Pediatrics
Clinical Director, Seaver Autism Center
Mount Sinai School of Medicine A Safety Study of NNZ-2566
from Neuren Pharmaceuticals
for males aged 14-40 years with Fragile X Syndrome
The webinar was held on 10/15/2014. PowerPoint Slides Here
This trial assesses the safety and efficacy of two dose levels of NNZ-2566. NNZ-2566 has a novel mechanism of action compared with other drugs that have been tested for Fragile X syndrome. It is a modified version of a biologically active part of Insulin-like Growth Factor-1 (IGF-1).
FDA has granted Fast Track Designation and Orphan Drug Designation for Neuren’s development of NNZ-2566 in Fragile X.
This webinar is intended for Fragile X families who want to learn more about this trial. It covers:
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)